L
Lorenz Trümper
Researcher at University of Göttingen
Publications - 276
Citations - 22696
Lorenz Trümper is an academic researcher from University of Göttingen. The author has contributed to research in topics: Lymphoma & Diffuse large B-cell lymphoma. The author has an hindex of 53, co-authored 260 publications receiving 19534 citations. Previous affiliations of Lorenz Trümper include Deutsche Forschungsgemeinschaft & University of Cologne.
Papers
More filters
Journal ArticleDOI
CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group.
Michael Pfreundschuh,Evelyn Kuhnt,Lorenz Trümper,Anders Österborg,Marek Trneny,Lois E. Shepherd,Devinder Gill,Jan Walewski,Ruth Pettengell,Ulrich Jaeger,Pier Luigi Zinzani,Ofer Shpilberg,Stein Kvaløy,Peter de Nully Brown,Rolf A. Stahel,Noel Milpied,Armando López-Guillermo,Viola Poeschel,Sandra Grass,Markus Loeffler,Niels Murawski +20 more
TL;DR: Rituximab added to six cycles of CHOP-like chemotherapy improved long-term outcomes for young patients with good-prognosis diffuse large-B-cell lymphoma and the definition of two prognostic subgroups allows a more refined therapeutic approach to these patients than does assessment by IPI alone.
Journal ArticleDOI
Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL.
Michael Pfreundschuh,Lorenz Trümper,Marita Kloess,Rudolf Schmits,Alfred C. Feller,Christian Rudolph,Marcel Reiser,Dieter K. Hossfeld,Bernd Metzner,Dirk Hasenclever,Norbert Schmitz,Bertram Glass,Christian Rübe,Markus Loeffler +13 more
TL;DR: Although the CHOEP regimens induced more myelosuppression, all regimens were well tolerated and CHOEP should be the preferred chemotherapy regimen for young patients with good-prognosis (normal LDH level) aggressive lymphoma.
Journal ArticleDOI
Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group.
Norbert Schmitz,Lorenz Trümper,Marita Ziepert,Maike Nickelsen,Anthony D. Ho,Bernd Metzner,Norma Peter,Markus Loeffler,Andreas Rosenwald,Michael Pfreundschuh +9 more
TL;DR: Patients with ALK-negative ALCL, PTCLU, or AITL presenting with IPI > 1 have a poor prognosis and should be considered candidates for novel treatment strategies.
Journal ArticleDOI
MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma
Heike Horn,Marita Ziepert,Claudia Becher,Thomas F. E. Barth,Heinz-Wolfram Bernd,Alfred C. Feller,Wolfram Klapper,Michael Hummel,Harald Stein,Martin-Leo Hansmann,Christopher Schmelter,Peter Møller,Sergio Cogliatti,Michael Pfreundschuh,Norbert Schmitz,Lorenz Trümper,Reiner Siebert,Markus Loeffler,Andreas Rosenwald,German Ott +19 more
TL;DR: A combined immunohistochemistry or FISH/immunohistochemical score predicts outcome in DLBCL patients independent of the IPI and identifies a subset of 15% of patients with dismal prognosis in the high-risk IPI group following treatment with R-CHOP.
Journal ArticleDOI
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
Steven M. Horwitz,Owen A. O'Connor,Barbara Pro,Timothy M Illidge,Michelle A. Fanale,Ranjana H. Advani,Nancy L. Bartlett,Jacob Haaber Christensen,Franck Morschhauser,Eva Domingo-Domenech,Giuseppe Rossi,Won Seog Kim,Tatyana Feldman,Anne Lennard,David Belada,Árpád Illés,Kensei Tobinai,Kunihiro Tsukasaki,Su-Peng Yeh,Andrei R. Shustov,Andreas Hüttmann,Kerry J. Savage,Sam Yuen,Swaminathan Padmanabhan Iyer,Pier Luigi Zinzani,Zhaowei Hua,Meredith Little,Shangbang Rao,Joseph Woolery,Thomas Manley,Lorenz Trümper +30 more
TL;DR: Front-line treatment with A+CHP is superior to CHOP for patients with CD30-positive peripheral T-cell lymphomas as shown by a significant improvement in progression-free survival and overall survival with a manageable safety profile.